In fact, our observation that tamoxifen can promote or maintain elevated levels of FXYD3 in the absence or diminished levels of ZEB1, contrary to the results obtained with estrogen exposure, might give some insight into a potential avenue through which tamoxifen might contribute to cancer progression, rather than suppression, in ER α-positive breast cancers. This evidence concerns the gene ZEB1 and cancer.